TY - JOUR T1 - Combinatorial analysis of phenotypic and clinical risk factors associated with hospitalized COVID-19 patients JF - medRxiv DO - 10.1101/2021.02.08.21250899 SP - 2021.02.08.21250899 AU - Sayoni Das AU - Matthew Pearson AU - Krystyna Taylor AU - Veronique Bouchet AU - Gert Lykke Møller AU - Taryn O. Hall AU - Mark Strivens AU - Kathy T. H. Tzeng AU - Steve Gardner Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/11/2021.02.08.21250899.abstract N2 - Characterization of the risk factors associated with variability in the clinical outcomes of COVID-19 is important. Our previous study using genomic data identified a potential role of calcium and lipid homeostasis in severe COVID-19. This study aimed to identify similar combinations of features (disease signatures) associated with severe disease in a separate patient population with purely clinical and phenotypic data.The PrecisionLife combinatorial analytics platform was used to analyze features derived from de-identified health records in the UnitedHealth Group COVID-19 Data Suite. The platform identified and analyzed 836 disease signatures in two cohorts associated with increased risk of COVID-19 hospitalization. Cohort 1 was formed of cases hospitalized with COVID-19 and a set of controls who developed mild symptoms. Cohort 2 included Cohort 1 individuals for whom additional laboratory test data was available.We found several disease signatures where lower levels of lipids were found co-occurring with lower levels of serum calcium and leukocytes. Many of the low lipid signatures were independent of statin use and 50% of cases with hypocalcemia signatures were reported with vitamin D deficiency. These signatures may be attributed to similar mechanisms linking calcium and lipid signaling where changes in cellular lipid levels during inflammation and infection affect calcium signaling in host cells.This study and our previous genomics analysis demonstrate that combinatorial analysis can identify disease signatures associated with the risk of developing severe COVID-19 separately from genomic or clinical data in different populations. Both studies suggest associations between calcium and lipid signalling in severe COVID-19.Competing Interest StatementAll authors are employees of their respective companies.Funding StatementNo external funding was used for this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed by the Office of Human Research Affairs (OHRA) of the UnitedHealth Group. The Federalwide Assurance number of OHRA is FWA00028881 and OHRP Registration number is IORG0010356. Ethical approval for this study was waived by OHRA with the following decision: The research was determined to be exempt category 4 given that the research involves secondary use of existing data (de-identified health records), there will be no interaction with participants and participant data will not be re-identified.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data analyzed in this study was obtained from UnitedHealth Group Clinical Discovery Portal. The data are proprietary and are not available for public use but, under certain conditions, may be made available to editors and their approved auditors under a data-use agreement to confirm the findings of the current study. Further inquiries can be directed to Scott Schneweis. ER -